2016年ACR/EULAR成人皮肌炎与多发性肌炎最小、中度与重大临床缓解标准
该国际协作项目通过专家调查、logistic回归和联合分析开发了基于6项核心组测量绝对百分比变化的连续评分模型,总改善评分范围0-100,最小、中度、重大改善阈值分别为≥20、≥40、≥60分,在皮肌炎/多发性肌炎患者队列中验证了高灵敏度和特异度。
要点
- 总改善评分基于6项核心组测量的绝对百分比变化及其相对权重求和。
- 最小、中度、重大改善阈值分别为总改善评分≥20、≥40、≥60分。
- 验证队列中三档改善的灵敏度/特异度分别为85%/92%、90%/96%、92%/98%。
核心结论
- 成人皮肌炎/多发性肌炎反应标准由基于6项核心组测量绝对百分比变化的联合分析模型构成,并设定了最小、中度、重大改善的阈值。
研究设计与样本
- 采用专家调查、logistic回归和联合分析开发了287个基于核心组测量的定义。
- 使用PAPRIKA方法确定核心组测量的相对权重和联合分析定义。
- 在患者概况上以专家共识为金标准评估定义性能,并用临床试验数据验证。
- 采用名义群体技术达成共识。
主要发现
- 共识达成基于6项核心组测量(医师、患者和肌肉外整体活动度、肌力、健康评估问卷和肌酶水平)绝对百分比变化的联合分析连续模型。
- 总改善评分范围为0-100,由各核心组测量的改善程度和相对权重求和确定。
- 在皮肌炎/多发性肌炎患者队列中,最小、中度、重大改善的灵敏度和特异度分别为85%和92%、90%和96%、92%和98%。
- 临床试验分析验证了定义可区分医师对改善的评级(P < 0.001)。
关键数值与推荐
- 最小改善阈值:总改善评分≥20分。
- 中度改善阈值:总改善评分≥40分。
- 重大改善阈值:总改善评分≥60分。
- 幼年皮肌炎采用相同标准但改善阈值不同。
临床怎么用
- 临床可依据6项核心组测量的绝对百分比变化计算总改善评分(0-100),按≥20、≥40、≥60分判定最小、中度、重大改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To develop response criteria for adult dermatomyositis (DM) and polymyositis (PM). METHODS: Expert surveys, logistic regression, and conjoint analysis were used to develop 287 definitions using core set measures. Myositis experts rated greater improvement among multiple pairwise scenarios in conjoint analysis surveys, where different levels of improvement in 2 core set measures were presented. The PAPRIKA (Potentially All Pairwise Rankings of All Possible Alternatives) method determined the relative weights of core set measures and conjoint analysis definitions. The performance characteristics of the definitions were evaluated on patient profiles using expert consensus (gold standard) and were validated using data from a clinical trial. The nominal group technique was used to reach consensus. RESULTS: Consensus was reached for a conjoint analysis-based continuous model using absolute percent change in core set measures (physician, patient, and extramuscular global activity, muscle strength, Health Assessment Questionnaire, and muscle enzyme levels). A total improvement score (range 0-100), determined by summing scores for each core set measure, was based on improvement in and relative weight of each core set measure. Thresholds for minimal, moderate, and major improvement were ≥20, ≥40, and ≥60 points in the total improvement score. The same criteria were chosen for juvenile DM, with different improvement thresholds. Sensitivity and specificity in DM/PM patient cohorts were 85% and 92%, 90% and 96%, and 92% and 98% for minimal, moderate, and major improvement, respectively. Definitions were validated in the clinical trial analysis for differentiating the physician rating of improvement (P < 0.001). CONCLUSION: The response criteria for adult DM/PM consisted of the conjoint analysis model based on absolute percent change in 6 core set measures, with thresholds for minimal, moderate, and major improvement.
引用
- Aggarwal R, Rider LG, Ruperto N, et al. 2016 American College of Rheumatology/European League Against Rheumatism Criteria for Minimal, Moderate, and Major Clinical Response in Adult Dermatomyositis and Polymyositis: An International Myositis Assessment and Clinical Studies Group/Paediatric Rheumatology International Trials Organisation Collaborative Initiative. Arthritis Rheumatol. 2017. PMID: 28382787. doi:10.1002/art.40064
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。